Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05184569 · ClinicalTrials.gov registry record · Phase 1
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
A Phase 1 study of Semantic Dementia, sponsored by Peter Ljubenkov, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 5
- Study locations
NCT05184569: Recruiting Phase 1 study of Semantic Dementia, sponsored by Peter Ljubenkov, MD.
NCT05184569 is a Phase 1 study of Semantic Dementia that is actively recruiting participants, run by Peter Ljubenkov, MD. The registered enrollment target is 64 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05184569, a Phase 1 study of Semantic Dementia, is actively recruiting participants, sponsored by Peter Ljubenkov, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
Primary Outcome
Assess adverse events during 6 months administration of Verdiperstat or Placebo
Conditions Studied
Interventions
- DRUG Verdiperstat
Study Locations (5)
California
- UCSF Memory and Aging Center - San Francisco
Illinois
- Northwestern University - Chicago
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- Houston Methodist Hospital - Nantz National Alzheimer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
What NCT05184569 shows while recruiting
NCT05184569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Semantic Dementia appearing as the primary indexed condition, and to 1 intervention - of which Verdiperstat is the first listed.
NCT05184569 lists 5 locations in 5 states (California, Illinois, Minnesota).
Frequently Asked Questions
What is clinical trial NCT05184569 about?
NCT05184569 is a clinical study titled "Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology". The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and...
What is the current status of trial NCT05184569?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2022-04-14. Estimated completion is 2026-09-30.
What conditions does trial NCT05184569 study?
This clinical trial studies the following conditions: Semantic Dementia.
What interventions are being tested in trial NCT05184569?
The interventions under investigation include: Verdiperstat (DRUG).
Who is sponsoring clinical trial NCT05184569?
This trial is sponsored by Peter Ljubenkov, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05184569 being conducted?
This trial has 5 study locations across California, Illinois, Minnesota, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Semantic Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05184569's enrollment target sits among peer trials
64 808th of 2000 higher than 1,181 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI